Google
CMMB — CHEMOMAB THERAPEUTICS LTD DRC (Healthcare >> Biotechnology)
CMMB FAQ
What is CMMB's ROE?
CHEMOMAB THERAPEUTICS LTD DRC reports a Return on Equity (ROE) of -69.72%.
What is CMMB's dividend yield?
CHEMOMAB THERAPEUTICS LTD DRC offers a dividend yield of 0.00%.
What is CMMB's Deepscope Quality Score?
Deepscope rates CMMB's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CMMB?
Deepscope's AI Timing Score for CMMB is 89 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CMMB belong to?
CHEMOMAB THERAPEUTICS LTD DRC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 1.77
Price
-0.03
(-1.67%)
Day Change
|
|
|---|
CMMB, the overall quality is not good ( Quality = 38) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.77 |
| PBV / Sector |
1.21 / 4.63
GOOD
|
| Earning Per Share | -1.02 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
0.09 M
GREAT
|
| Average 1W Daily Value |
0.10 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:29 |
| Symbol | CMMB |
| Name | CHEMOMAB THERAPEUTICS LTD DRC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 7.20 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 12.96 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Building C, Tel Aviv, Israel, 6158101
Phone: 972 77 331 0156
Website: https://www.chemomab.com
Sector: Healthcare >> Biotechnology
Description: Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
